Tag results:

tumor-infiltrating lymphocytes

Engineering Strategies to Enhance Oncolytic Viruses in Cancer Immunotherapy

[Signal Transduction and Targeted Therapy] Scientists summarize the intrinsic mechanisms of oncolytic viruses (OVs), describe the optimization strategies for using armed OVs to enhance the effects of antitumor immunity, and highlight rational combinations of OVs with other immunotherapies in recent preclinical and clinical studies.

Pinpointing the Tumor-Specific T Cells via TCR Clusters

[eLife] The authors demonstrated that homology cluster analysis of T cell receptor (TCR) repertoires efficiently identified tumor-reactive TCRs.

UV-Induced Local Immunosuppression in the Tumour Microenvironment of Eccrine Porocarcinoma and Poroma

[Scientific Reports] Investigators characterized the distribution of tumor infiltrating lymphocytes (TILs) and TLSs using CD3, CD4, CD8, CD20 immunohistochemistry in a cohort of 10 eccrine porocarcinoma (EPCs) and 49 EPs.

Tim-3 Mediates T Cell Trogocytosis to Limit Antitumor Immunity

[Journal of Clinical Investigation] Scientists showed that human PD-1+Tim-3+ CD8+ tumor-infiltrating lymphocytes upregulated phosphatidylserine, a receptor for Tim-3, and acquire cell surface myeloid markers from antigen presenting cells through transfer of membrane fragments called trogocytosis.

Ferroptosis, Necroptosis, and Pyroptosis in the Tumor Microenvironment: Perspectives for Immunotherapy of SCLC

[Seminars in Cancer Biology] Scientists summarize the roles of distinct immunogenic cell death mechanisms on antitumor immunity and recent advances of ferroptosis-, necroptosis- and pyroptosis-inducing agents, and present perspectives on these cell death mechanisms in immunotherapy of SCLC.

MYC Inhibition Reprograms Tumor Immune Microenvironment by Recruiting T Lymphocytes and Activating the CD40/CD40L System in Osteosarcoma

[Cell Death Discovery] Scientists found that the expression of the c-Myc oncogene was negatively correlated with T cell infiltration rate in osteosarcoma. Pharmacological inhibition of c-Myc with JQ-1 significantly reduced tumor burden and improved overall survival in an immunocompetent syngeneic murine model of osteosarcoma.